Featuring Michael F. Cannon, Director of Health Policy Studies, Cato Institute; Peter Van Doren, Senior Fellow and Editor, Regulation, Cato Institute; moderated by Matt Weibel, Director of Government & External Affairs, Cato Institute.
In response to bipartisan outrage over drug prices, which have risen dramatically in recent years, the Trump administration has proposed adjusting rules that determine how much the Medicare program and Medicare enrollees will pay for pharmaceuticals.
Some conservatives oppose these changes and defend the current pricing system on free-market grounds, arguing that reducing drug prices will necessarily reduce innovation.
What is the “right” price for prescription drugs? What is the price Medicare should pay? Join our panelists as they explain the current drug pricing system, the Trump administration’s efforts to reform it, and bipartisan ways to address the problem.
If you can’t make it to the event, you can watch it live online at www.cato.org/live and join the conversation on Twitter using#CatoHillEvents. Follow @CatoEvents on Twitter to get future event updates, live streams, and videos from the Cato Institute.